Desmoplakin maintains gap junctions by inhibiting Ras/MAPK and lysosomal degradation of connexin-43.
Desmoplakin (DP) is an obligate component of desmosomes, intercellular adhesive junctions that maintain the integrity of the epidermis and myocardium. Mutations in DP can cause cardiac and cutaneous disease, including arrhythmogenic cardiomyopathy (ACM), an inherited disorder that frequently results in deadly arrhythmias. Conduction defects in ACM are linked to the remodeling and functional interference with Cx43-based gap junctions that electrically and chemically couple cells. How DP loss impairs gap junctions is poorly understood. We show that DP prevents lysosomal-mediated degradation of Cx43. DP loss triggered robust activation of ERK1/2–MAPK and increased phosphorylation of S279/282 of Cx43, which signals clathrin-mediated internalization and subsequent lysosomal degradation of Cx43. RNA sequencing revealed Ras-GTPases as candidates for the aberrant activation of ERK1/2 upon loss of DP. Using a novel Ras inhibitor, Ras/Rap1-specific peptidase (RRSP), or K-Ras knockdown, we demonstrate restoration of Cx43 in DP-deficient cardiomyocytes. Collectively, our results reveal a novel mechanism for the regulation of the Cx43 life cycle by DP in cardiocutaneous models.

**Introduction**

Maintenance of tissue homeostasis and integrity is achieved through highly specialized membrane–cytoskeleton attachment sites. The most prominent of these in the epidermis and myocardium are desmosomes, which are cadherin-based junctional complexes that tether the intermediate filament (IF) cytoskeleton to sites of cell–cell adhesion (Leung et al., 2002; Green and Simpson, 2007). In both epithelial and cardiac cells, desmosomes are structurally and functionally associated with actin-associated adherens junctions, which organize the cortical actin cytoskeleton, and connexin-containing gap junctions, which are pore-like structures that allow for the passage of small molecules and ions between two neighboring cells (Saéz et al., 2003; Laird, 2006; Goodenough and Paul, 2009). In cardiomyocytes, close association between junctions is facilitated by intercalated discs (IDs), which are present where cardiomyocytes meet end to end and serve to integrate force transmission and electrical coupling in the heart (Forbes and Sperelakis, 1985). The ID in adult mammals is further specialized to form the area composita, in which adherens junction and desmosome components are intermixed, further stabilizing the junction (Goossens et al., 2007; Pieperhoff and Franke, 2007; Pieperhoff et al., 2008).

The desmosomal component that physically links the transmembrane desmosomal cadherin complex to the IF cytoskeleton is desmoplakin (DP), a requisite mediator of mechanical strength in skin and heart. The importance of DP is underscored by the failure of DP-null murine embryos to survive beyond embryonic day 6.5 (E6.5) because of destabilization of desmosomes leading to egg cylinder elongation defects (Gallicano et al., 1998). Tetraploid analysis and tissue-specific conditional knockouts (KOs) later demonstrated a requirement for DP in vascular development, epidermal integrity, and cardiac function (Gallicano et al., 2001; Vasioukhin et al., 2001; Lyon et al., 2014). In the case of heart, conditional DP KO recapitulated the pathology of the human cardiac disease arrhythmogenic cardiomyopathy (ACM), which has been associated with mutations in desmosomal components (Asimaki and Saffitz, 2014; Lyon et al., 2014). Pathogenic DP mutations are the second most frequently identified in ACM and can be present either with or without cutaneous phenotypes (Alcalai et al., 2003; López-Ayala et al., 2014; Molho-Pessach et al., 2015; Castelletti et al., 2017). In ACM, healthy myocardium is progressively replaced with fibrofatty tissue deposits that can ultimately lead to ventricular arrhythmias and sudden cardiac death...
The idea that loss of DP interferes with both transcriptional and with our previous work (Patel et al., 2014), these data support cued Cx43 expression and localization caused by DP loss. Along this line, interference with normal integration of intercellular junctions and functional dynamics of intercellular junctions and how myocytes provide an ideal model for studying the structural regulation of connexin-43 degradation by desmoplakin (Kam et al., 2012; Lyon et al., 2014). However, the molecular mechanisms by which desmosomal mutations lead to disease pathogenesis are not well understood.

While desmosomal and adherens junctions components of the ID facilitate mechanical coupling between neighboring cardiomyocytes, evidence suggests that they are physically and functionally integrated with gap junctions and sodium channels to facilitate electrical conduction at these nodes (Saez et al., 2003; Laird, 2006; Goodenough and Paul, 2009; Stroemlund et al., 2015). Vertebrate gap junctions are made up of proteins from the 21-gene connexin family, whereby hexamers of connexin proteins (termed connexons) formed on two adjacent cells dock with each other to produce channels that allow for the passage of small molecules and ions (Laird, 2006; Goodenough and Paul, 2009). Of these members, connexin-43 (Cx43) is the most ubiquitously expressed connexin in many tissues and cultured cells (Laird, 2006). We previously showed that DP plays an important role in the delivery of Cx43 to the plasma membrane via an EBI-microtubule-dependent pathway (Patel et al., 2014). In addition, two independent mouse models with cardiac conditional DP KO (DPeKO) reported that DP loss also leads to a significant reduction in Cx43 protein levels (Gomes et al., 2012; Lyon et al., 2014). The loss of Cx43 expression in these models was speculated to contribute to a feature of ACM called the “concealed phase,” in which electrical conduction defects occur before fibrofatty replacement of healthy myocardium (Saffitz et al., 2010; Gomes et al., 2012; Lyon et al., 2014). However, the molecular mechanism by which loss of DP leads to a decrease in Cx43 is unknown. Given the unique organization of cardiac cell junctions, cardiomyocytes provide an ideal model for studying the structural and functional dynamics of intercellular junctions and how interfering with normal integration of intercellular junctions leads to disease (Garcia-Gras et al., 2006; Cerrone et al., 2012, 2014; Lyon et al., 2014).

In this study, we characterize a novel mechanism by which DP loss leads to Cx43 protein degradation. Depletion of DP triggers robust activation of the ERK1/2–MAPK pathway, resulting in phosphorylation of residues S279 and 282 within the intracellular C terminus of Cx43. These consensus ERK1/2 phosphorylation sites are known to be phosphorylated in tandem to mark Cx43 for degradation (Fong et al., 2014). We further show that DP loss elevates mRNA, protein, and activity of the canonical upstream activator of ERK1/2, K-Ras, in cardiac cells but not in an epidermal model of DP loss. Inhibition of Ras using either K-Ras knockdown (KD) or a novel peptide inhibitor derived from a toxin secreted by the bacterium Vibrio vulnificus rescued Cx43 expression and localization caused by DP loss. Along with our previous work (Patel et al., 2014), these data support the idea that loss of DP interferes with both transcriptional and posttranslational mechanisms controlling Cx43 expression and localization and provide a new perspective on the molecular events leading to cardiac arrhythmias and other connexin-based disorders in skin and heart.

**Results**

**DP loss impairs the expression and localization of the gap junction protein Cx43**

Previous studies showed that DP loss is associated with decreased expression of Cx43 in cardiac tissue (Gomes et al., 2012; Lyon et al., 2014). Toward determining the mechanism by which DP regulates Cx43 protein levels, we used cultured neonatal rat ventricular cardiomyocytes (NRVCs) and the HL-1 mouse atrial cardiomyocyte line (Claycomb et al., 1998). Previous in vitro analyses comparing primary cardiomyocytes and HL-1 cells with in vivo models of cardiac disease demonstrated the utility of these cell culture models for defining molecular mechanisms underlying desmosome-related cardiac disorders (Garcia-Gras et al., 2006; Cerrone et al., 2012, 2014; Lyon et al., 2014).

To verify the dependence of Cx43 protein levels on the presence of DP in vitro, freshly isolated NRVCs were treated with an adenovirus harboring either control (nontargeting) or DP KD shRNA constructs, and HL-1 cells were transfected with either control or DP KD-specific siRNA. In both cardiac cell types, depletion of DP resulted in a substantial decrease in Cx43 protein levels, consistent with that observed in a cardiac restricted mouse model harboring DP deletion (Fig. 1, A and A’; Lyon et al., 2014). Furthermore, the fluorescence intensity of Cx43 staining at cell–cell junctions was substantially reduced in DP KD cardiomyocytes compared with controls (Fig. 1, B and B’). DP loss did not detectably alter the expression or distribution of other cardiac junctional components whose disruption might have contributed to the observed decrease in Cx43, including plakoglobin (Pg), N-cadherin, and α-catenin (Fig. 1, C and D). Although DP KD resulted in a small decrease in plakophilin 2 (PKP2) levels (Fig. 1 C), we previously showed that DP can restore defects resulting from PKP2 loss (Dubash et al., 2016).

To test whether the loss of DP is responsible for the observed decrease in Cx43 protein levels, we assessed whether expression of exogenous DP was sufficient to recover Cx43 expression. To achieve this, DPII-GFP was delivered using an adenovirus in the background of DP KD. DPII is a naturally occurring isoform of DPI that is lacking in the rod domain (6.8 vs. 8.6 kb). This construct was used to overcome technical limits in size for adenoviral packaging and transduction. Like DPI, DPII is localized to desmosomes and confers adhesive strength to cell–cell junctions (Angst et al., 1990; Green et al., 1990; Cabral et al., 2012; Patel and Green, 2014). Expression of full-length DPII was sufficient to restore Cx43 localization to cell junctions as assessed by immunofluorescence (Fig. 1, E and E’). Additionally, DPII expression restored Cx43 protein to control levels in the background of DP KD as assessed by Western blot (Fig. 1, F and F’). Collectively, these data demonstrate that DP is essential for the stable expression of Cx43 protein and its incorporation into gap junctions in cardiac cells.
Kam et al.
Regulation of connexin-43 degradation by desmoplakin

Journal of Cell Biology
https://doi.org/10.1083/jcb.201710161

Numerical and graphical data are shown to illustrate the regulation of connexin-43 degradation by desmoplakin. Bar graphs and immunofluorescence images are presented to depict the changes in protein levels and membrane intensity following knockdown (KD) of different proteins.

A. Western blot analysis of connexin-43 (Cx43) protein levels in HL1 and NRVM Cx43. DP (desmoplakin) knockdown (KD) results in a significant decrease in Cx43 levels compared to control (CT).

B. Immunofluorescence images of Cx43 expression in NRVM Cx43. Cx43 levels are reduced in DP KD compared to CT KD.

C. Western blot analysis of Cx43, PKP2, and α-Catenin protein levels in NRVM Cx43. PKP2 and α-Catenin levels are unaffected by DP KD, while Cx43 levels are decreased.

D. Immunofluorescence images of PKP2, N-Cadherin, and β-Catenin expression in NRVM Cx43. PKP2 and N-Cadherin levels are not significantly affected by DP KD, while β-Catenin levels are reduced.

E. Immunofluorescence images showing Cx43 association with PKP2 and N-Cadherin in NRVM Cx43. Cx43 levels are decreased in DP KD compared to CT KD.

F. Western blot analysis of Cx43 protein levels in NRVM Cx43 with DP KD and DP KD + DPI (pimeloyl carnitine). Cx43 levels are further decreased with DPI treatment.
DP loss results in elevated phosphorylation of Cx43 at MAPK-regulated S279/282 sites

Connexins exhibit short half-lives on the order of 1–5 h compared with other membrane proteins, which typically exhibit half-lives on the order of 24–48 h (Laird et al., 1991; Beardslee et al., 1998). Gap junctions are therefore highly dynamic structures that are constantly undergoing assembly, remodeling, and turnover (Solan and Lampe, 2014). Posttranslational modification of Cx43, particularly phosphorylation, has been extensively studied as a mechanism by which gap junction dynamics are regulated. Of the 26 serines in the intracellular serine-rich C-terminal region of Cx43, at least 19, along with two of six tyrosines, have been identified as phosphorylation sites (Axelsen et al., 2013). Given the importance of phosphorylation for the connexin life cycle, we asked whether DP plays a role in modulating Cx43 phosphorylation. To address this question, control and DP KD NRVCMS were tested with phosphosite-specific Cx43 antibodies (Márquez-Rosado et al., 2012). Interestingly, an increase in phosphorylation of a linked pair of Cx43 sites at S279/282 was detected in response to DP KD (Fig. 2 A). Phosphorylation at this pair has been implicated in down-regulation of gap junction intercellular communication as well as internalization and degradation of Cx43 (Norris et al., 2008; Johnson et al., 2013; Fong et al., 2014). When normalized to total Cx43 protein levels that are reduced in the absence of DP, the ratio of p-Cx43 S279/282 to total Cx43 increased approximately fourfold in DP KD NRVCMS (Fig. 2 A’).

As phosphorylation at Cx43 S279/282 sites is mediated by ERK1/2, we tested whether depletion of DP affects activation of the ERK1/2–MAPK pathway (Warn-Cramer et al., 1996). Indeed, by Western blot, robust activation of p-ERK1/2 levels was observed in response to DP KD in NRVCMS (Fig. 2 B and B’). The original observation that DP loss leads to reduced Cx43 protein expression was made in a cardiac conditional KO mouse model (Lyon et al., 2014). To test whether DP loss leads to increased p-Cx43 S279/282 in cardiac tissue, immunofluorescence analysis was performed on cardiac sections from the aforementioned DpcKO mouse. Cx43 staining intensity at the IDs of DpcKO heart sections was significantly decreased compared with WT (Fig. 2, C and C’). However, DpcKO cardiac sections display elevated levels of p-Cx43 S279/282 staining compared with WT (Fig. 2 C). Quantification of p-Cx43 S279/282 normalized to total Cx43 at IDs (as marked by Pg staining) revealed an approximate fourfold increase in the p-Cx43/total Cx43 ratio in DpcKO versus WT hearts (Fig. 2 C’).

To determine whether the observed loss of Cx43 was associated with a functional loss of gap junction intercellular communication (GJIC), scrape loading dye transfer assays were performed. HL-1 cells grown to a confluent monolayer were scraped and treated with the gap junction permeable dye Lucifer Yellow (LY). GJIC was evaluated by the number of cells displaying positive LY signal, indicative of level of dye transfer between neighboring cells. DP depletion resulted in a significant reduction in LY signal transferred between cells compared with control (Fig. 2, D and D’). Furthermore, reexpression of full-length DPII restored levels of dye transfer to that of control cells (Fig. 2, D and D’). These data demonstrate that the decreased expression and assembly of Cx43 into gap junctions caused by DP loss perturbs gap junction function.

Cx43 phosphorylation is altered in ACM

To determine whether this pathway has relevance in ACM, a blinded experiment was performed using cardiac sections from healthy controls or ACM patients harboring pathogenic mutations in DP or PKP2. All patient samples discussed in this section are unpublished. Immunofluorescence analysis of total Cx43 and p-Cx43 S279/282 was assessed, and in parallel, DP staining was performed to evaluate the consequence of the mutations to DP’s localization at IDs. Healthy control tissue displayed strong total Cx43 signal at IDs (Fig. 3 B and S1 A). Additionally, control sections did not show appreciable ID or cytoplasmic p-Cx43 S279/282 signal (Fig. 3 B). In contrast, cardiac tissue from two of the ACM patients harboring mutations in DP at 1,218+1 G→A and C333T, respectively, displayed almost complete loss of total Cx43. The only detectable signal was nonspecific lipofuscin autofluorescence (Fig. S1 A, white arrowheads). These data are consistent with the reported loss of Cx43 from IDs of both DP ACM and Carvajal syndrome (cardiocutaneous syndrome caused by DP mutations) patients (Kaplan et al., 2004; Asimaki et al., 2009; Gomes et al., 2012). Assessment of p-Cx43 S279/282 could not be performed in these patients as we could not detect appreciable total Cx43 signal. Both patients also showed severe impairment of DP localization to IDs as marked by Pg staining compared with healthy controls (Fig. S1, B and B’).

In contrast, analysis of DP ID localization in cardiac tissue from an ACM patient harboring a pathogenic mutation in PKP2 at 971_980del10 showed significantly impaired (Fig. 3 A, white arrowheads) but not complete loss of DP from IDs compared with control (Fig. 3 A inset and Fig. 3 A’). The loss of DP resulting from a PKP2 mutation is consistent with our previous work showing that PKP2 loss in cardiac cells promotes the destabilization of DP protein and its subsequent degradation.

Figure 1. DP KD results in decreased levels of Cx43 in cardiac cells. (A) NRVCMS and HL-1 cells were treated with DP-specific shRNA and siRNA, respectively, and samples were analyzed 72 h after infection/transfection. DP KD leads to a significant reduction of Cx43 protein levels in both cell types (HL-1, n = 4; NRVCMS, n = 6). (A’) Densitometry quantification of Cx43 levels normalized to loading control. DP KD leads to a significant reduction of Cx43 protein levels in both cell types (HL-1, n = 4; NRVCMS, n = 6). (A’) Densitometry quantification of Cx43 levels normalized to loading control. DP KD results in a decrease of Cx43 junctional localization (n = 5). (B’) Quantification of Cx43 membrane intensity (normalized to junctional Pg signal) in control and DP KD NRVCMS. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by two tailed Student’s t test. (C) Control and DP KD NRVCMS were blotted for the following cardiac junctional components: DP, PKP2, Pg, N-cadherin, and α-catenin (n = 3). Densitometry quantification is representative of three independent experiments. (D) Control and DP KD NRVCMS were blotted for the following cardiac junctional components: DP, PKP2, Pg, N-cadherin, α-catenin, and β-catenin (n = 3). (E and E’) Re-expression of full-length human DPII rescues Cx43 junctional localization in NRVCMS (n = 3). Quantification of junctional Cx43 (normalized to Pg) shows that DPII expression causes a significant restoration of Cx43 membrane localization. Bars, 20 μm. (F) Re-expression of DPII restores Cx43 protein levels in NRVCMS by Western blot (n = 3). (F) Densitometry quantification of Cx43 levels normalized to loading control. Error bars represent mean ± SD. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by one-way ANOVA followed by Tukey’s post hoc test.
via the proteasome (Dubash et al., 2016). Furthermore, this patient displayed significantly lowered Cx43 ID staining compared with control without complete loss of expression (Fig. 3, B and B′). This patient’s cardiac tissue showed an approximately threefold increase in p-Cx43 S279/282 to total Cx43 (Fig. 3 B″), reminiscent of elevated p-Cx43 S279/282 signal seen in DPcKO murine hearts (Fig. 2 C). The milder Cx43 phenotype observed in this ACM patient compared with those harboring pathogenic DP mutations may have resulted from the presence of residual DP at IDs.
Elevated phosphorylation of Cx43 at S279/282 is conserved in an epidermal restricted DP mouse KO model

In addition to cardiocutaneous disorders such as Carvajal syndrome, dominant de novo DP mutations have recently been reported to cause erythrokeratoderma–cardiomyopathy syndrome associated with impaired Cx43 membrane localization in the skin (Boyden et al., 2016). Thus, we next addressed whether DP regulates Cx43 levels in the epidermis, where it plays a vital role in epidermal proliferation and differentiation (Norgett et al., 2000; Langlois et al., 2007, 2010), using an epidermal conditional KO mouse model of DP (DPeKO; Vasioukhin et al., 2001). Immunofluorescence analysis demonstrated that the previously reported abnormal morphology in DPeKO epidermis was accompanied by significantly lower Cx43 membrane staining (Fig. 4,
We also observed an increase in p-Cx43 S279/282 levels in DPeKO samples compared with WT by Western blot (Fig. 4 B) and immunofluorescence (Fig. 4, C and C′), paralleling what was observed in cardiac cells. Furthermore, the ratio of p-Cx43 S279/282 to total Cx43 levels revealed an approximately twofold increase in DPeKO samples compared with WT (Fig. 4 B′). Accompanying the observed changes in Cx43, p-ERK1/2 levels increased in DPeKO epidermis compared with WT (Fig. 4 B). Collectively, these data suggest that DP-dependent regulation of Cx43 phosphorylation at the p-ERK1/2–MAPK-specific residues, S279/282, is a conserved mechanism in cardiac and cutaneous models.

**DP loss leads to elevated ubiquitination and degradation of Cx43**

Phosphorylation of Cx43 at S279/282 has been shown to trigger internalization and degradation of Cx43 (Fong et al., 2014). To test whether depletion of DP leads to degradation of Cx43 in cardiac cells, Cx43 protein stability was analyzed in response to DP KD by treating HL-1 cells with cycloheximide for the indicated times. Cx43 protein degraded at a higher rate in DP KD cells compared with control (Fig. 5, A and A′). Quantitative PCR (qPCR) analysis showed that DP KD did not have a significant effect on Cx43 transcript levels in NRVCs, suggesting that DP-dependent regulation of Cx43 expression does not occur at the mRNA level (Fig. S2). Degradation of Cx43 has been shown to occur via either the proteasomal or lysosomal pathways depending on cell type and degradation stimulus (Laing et al., 1997; Leithe and Rivedal, 2004; Leithe et al., 2006). To identify the machinery responsible for Cx43 degradation in response to DP loss, we used the proteasomal inhibitor MG132 or the lysosomal inhibitor chloroquine in the background of DP KD. Surprisingly, MG132 treatment resulted in a decrease in Cx43 expression in control cells without decreasing DP levels (Fig. 5 B). MG132 treatment further decreased the levels of Cx43 observed upon DP KD (Fig. 5 B). In contrast, chloroquine treatment caused an accumulation Cx43 protein levels in control cells and restored Cx43 expression in DP KD cells. These data are consistent with lysosomal-mediated degradation of Cx43 at steady state, which is exacerbated by loss of DP (Fig. 5 C).

Cx43 is modified by ubiquitination, a tag that is thought to target the connexin for subsequent degradation (Laing and Beyer, 1995; Leithe and Rivedal, 2004; Chen et al., 2012).
Figure 5. Loss of DP promotes ubiquitination and degradation of Cx43. (A) Control and DP KD HL-1 cells were treated with cycloheximide for the indicated time points, and samples were blotted for DP and Cx43 (n = 4). (A') Densitometry quantification was performed to assess rate of Cx43 degradation. (B) MG132 was used to assess role of proteasomal degradation of Cx43 caused by DP loss in NRVCMs (n = 3). (C) The lysosomal inhibitor Chloroquine was able to restore Cx43 expression levels in response to DP KD in NRVCMs (n = 3). (D) Cx43 was immunoprecipitated from control and DP KD NRVCMs. Samples were subsequently blotted for Cx43 and ubiquitin. Whole-cell lysate (WCL) from these samples is to the right (n = 4). (E and E') WT and DPeKO epidermal sections were subjected to PLA analysis with Cx43 and ubiquitin antibody pairs (n = 3). Bar, 20 µm. Quantification of PLA dots normalized to DAPI count revealed a significant increase in Cx43-Ubiquitin PLA in DPeKO compared with WT skin. Error bars represent mean ± SD. **, P < 0.01; ***, P < 0.001 by two-tailed Student’s t test.

Determine whether Cx43 is ubiquitinated in response to DP loss, immunoprecipitates of endogenous Cx43 from control and DP KD NRVCMs were immunoblotted for endogenous ubiquitin. Using the mono/polyubiquitin antibody FK2, it was observed that Cx43 is more highly ubiquitinated in DP KD samples compared with control (Fig. 5 D). To determine whether increased ubiquitination of Cx43 is conserved in mouse epidermis lacking DP, proximity ligation assay (PLA) was used to detect ubiquitin modification of Cx43 in mouse tissue sections. PLA allows for the in situ visualization of two antigens that are in close proximity to each other (40–100 nm). This assay is used frequently to detect posttranslational modifications on target proteins (Fredriksson et al., 2002; Söderberg et al., 2006; Ristic et al., 2016). DPeKO epidermis produced significantly more Cx43-Ub PLA signal compared with WT, suggesting that DP-dependent ubiquitination of Cx43 is conserved in the heart and skin (Fig. 5, E and E').

Blockade of Cx43 phosphorylation is sufficient to rescue Cx43 expression and localization

Our data suggest that DP loss activates p-ERK1/2–MAPK, which in turn phosphorylates Cx43 on S279/282 to target Cx43 for degradation. To directly test whether preventing Cx43 phosphorylation blocks degradation and restores junctional localization of Cx43, DP KD NRVCMs were treated with U0126, a small-molecule inhibitor of MEK1/2, the direct upstream activator of p-ERK1/2. U0126 treatment restored p-ERK1/2 and total Cx43 expression levels to those of control (Fig. 6 A). Additionally, when normalized to total Cx43 levels, the p-Cx43 S279/282 signal was also restored to a level comparable with control (Fig. 6 A').

Immunofluorescence analysis using Pg as a marker of cell junctions revealed that U0126 treatment also partially restores localization of Cx43 to cell junctions (Fig. 6, B and B'). The difference in restoration between protein levels and localization may...
be explained by our previous demonstration that DP also functions posttranslationally to promote the delivery of Cx43 to cell junctions via microtubules (MTs) in keratinocytes via an association with MT plus end protein EB1 (Patel et al., 2014). These data suggest that blocking the initial phosphorylation of Cx43 by p-ERK1/2 is sufficient to prevent Cx43 loss in DP-deficient conditions and to help restore membrane localization of Cx43, where it can be assembled into gap junction complexes.

DP inhibits the ERK–MAPK pathway via suppression of RAS

Toward identifying candidate mechanisms by which DP loss activates the ERK1/2–MAPK pathway, we compared control and DPKD NRVCMs using large-scale unbiased RNA sequencing (RNA-seq) analysis. Notably, levels of V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) RNA were significantly up-regulated in DP KD samples. KRas is one of the three major isoforms of the Ras GTPase family, which include H-Ras and N-Ras (Castellano and Santos, 2011; Hobbs et al., 2016). Mutations in these proteins frequently lead to malignancies, with gain-of-function missense mutations in RAS genes having been found in ~25% of human cancers (Hobbs et al., 2016). Ras is well known to initiate a signaling cascade involving the subsequent activation of the Raf–MEK–ERK pathway (Roberts and Der, 2007). To validate DP’s regulation of Ras transcript levels, qPCR analysis of the three major Ras isoforms (KRAS, HRAS, and NRAS) was compared in control and DP KD NRVCMs. Depletion of DP resulted in significant increases of K-Ras and H-Ras transcript levels but not of N-Ras (Fig. 7 A).

Because the KRAS transcript displayed the most substantial increase (sevenfold), we assessed K-Ras protein levels in response to DP KD. Western blot analysis showed that K-Ras protein expression is elevated in DP KD cells compared with control (Fig. 7, B and B′). The protein kinase c-Raf directly binds to GTP-loaded Ras proteins to propagate the MAPK pathway via the subsequent phosphorylation and activation of MEK, the kinase that in turn phosphorylates and activates ERK1/2 (Roberts and Der, 2007). As such, we exploited PLA to measure Ras–Raf interactions as an indicator of elevated Ras activation in vivo under DP KO conditions. K-Ras/c-Raf PLA signal was significantly increased in DPcKO hearts compared with WT, affirming that DP-dependent Ras activation is conserved in vivo (Fig. 7, C and C′).

Toward determining whether K-Ras is responsible for DP-dependent activation of the ERK1/2–MAPK pathway, we used a recently described bacterial toxin-derived Ras/Rap1-specific peptidase (RRSP; Antic et al., 2015). RRSP’s ability to inhibit Ras activity in mammalian cells is notable as Ras proteins have been notoriously difficult to target pharmacologically (Cox et al., 2014). RRSP is derived from DUF5Vv (domain of unknown function in fifth position), a naturally occurring effector domain from the multifunctional-autoprocessing-repeats-in-toxins (MAR TX) toxin of the bacterium V. vulnificus (Antic et al., 2015; Biancucci et al., 2017). This protein represents a new class of endopeptidase that specifically processes all three major Ras isoforms as well as Rap1, blunting their activity and downstream activation of the ERK1/2–MAPK pathway, and which has so far been tested solely on cancer cell lines in an in vitro setting (Antic et al., 2015).

RRSP was functionalized for delivery into cells by fusion of the DUF5v domain to the N terminus of anthrax toxin lethal factor (LFNDUF5Vv), followed by introduction of the fusion protein to NRVCMs using anthrax protective agent (PA; Antic et al., 2015). RRSP effectively reduced p-ERK1/2 levels in NRVCMs, consistent with dampened Ras activation (Fig. S3). Having validated RRSP efficacy in cardiomyocytes, we next tested whether RRSP would be able to rescue DP-dependent Ras activation. We used a Ras-GTP antibody that specifically recognizes Ras in its GTP-bound active state. Immunofluorescence analysis revealed that
DP KD resulted in a significant up-regulation of Ras-GTP signal, which was restored to control levels with RRSP treatment (Fig. 7, D and D'). RRSP treatment also efficiently inhibited p-ERK1/2 activation that occurred in response to DP KD (Fig. 7 E).

To confirm that RRSP suppresses p-ERK by inhibiting K-Ras, we generated shRNA specific to K-Ras and showed that it is capable of knocking down K-Ras along with a concurrent decrease in p-ERK1/2 in NRVMCs (Fig. 7 F). We next performed a double KD of K-Ras and DP and showed that silencing of K-Ras reduced p-ERK1/2 back to control levels in DP-deficient NRVMCs, indicating that DP-dependent activation of the ERK1/2–MAPK pathway is caused by elevated K-Ras signaling (Fig. 7 G). As robust activation of ERK1/2–MAPK signaling was observed in an epidermal model of DP deletion (Fig. 4 B), we addressed whether DP's effects on Ras expression are conserved in the skin. qPCR analysis revealed that transcript levels of all three major Ras isoforms are not significantly changed in DpeKO epidermis compared with WT (Fig. S4). This finding is consistent with the idea that ERK1/2–MAPK activation depends on factors other than modulation of Ras mRNA levels in DpeKO epidermis.

To determine whether ERK-dependent reduction of Cx43 depends on K-Ras in DP-deficient cells, we assessed Cx43 levels in RRSP-treated or K-Ras KD NRVMCs. Both RRSP and K-Ras shRNA restored total Cx43 as well as the ratio of p-Cx43 S279/282 to that of control samples (Fig. 7, E, E', G, and G'). Similar to U0126 treatment, RRSP also significantly restored Cx43 localization to cell junctions in NRVMCs in DP KD cells (Fig. 7, H and H'). Finally, DPII expression in the background of DP KD was sufficient to restore K-Ras, p-ERK1/2, and the ratio of p-Cx43 S279/282 to total Cx43 levels to that of control (Fig. 7, I and I').

**Discussion**

This work reveals a novel mechanism by which DP keeps Ras in check to stabilize Cx43 in the gap junctions of cardiomyocytes. Upon loss of DP either in vitro or in vivo, ERK1/2–MAPK signaling is activated, resulting in phosphorylation of Cx43 at S279/282, an event that signals Cx43 for degradation that is performed via the lysosome (Fig. 8). This finding provides new insight into the role of the heart caused by increased cardiomyocyte size (Wang, 2007; Lorenz et al., 2009). Thus, it is plausible that abnormal ERK2 signaling could contribute to disease pathogenesis including cardiomyocyte hypertrophy in cardiac patients harboring mutations in DP (or factors that regulate its expression or localization). In epithelial cells, both activation of ERK2 signaling and loss or impairment of DP can lead to altered proliferation, migration, and differentiation (Matsubayashi et al., 2004; Setzer et al., 2004; Khavari and Rinn, 2007; Yang et al., 2012). That depletion of DP in the HaCaT keratinocyte cell line resulted in increased proliferation associated with elevated p-ERK1/2 levels is consistent with the concealed phase of ACM (Asimaki and Saffitz, 2012; Lyon et al., 2014). Our data provide a potential explanation for how DP loss could contribute to the concealed phase through regulation of Cx43 protein levels via modulation of Cx43 posttranslational modifications.

We identified Ras as a key link between DP and Cx43 regulation. Inhibition of Ras activity using a novel Ras inhibitor, RRSP, or by silencing with shRNA targeting K-Ras, demonstrated that ERK1/2 activation and associated loss of Cx43 expression was mediated by increased Ras expression and activity in DP-deficient cells. How DP regulates Ras mRNA levels is not yet understood. Although regulatory mechanisms controlling Ras transcription are not well characterized, one possibility is that loss of DP enhances the rate of Ras gene transcription via activation of transcription factors/cofactors. DP-dependent regulation of Ras transcript levels could also be through epigenetic mechanisms, for instance via the action of specific microRNAs that have been shown to be responsible for controlling Ras expression levels in various cell types (Shin et al., 2011; Wang et al., 2014; Zhang et al., 2014). To date, there have been no pharmacological inhibitors of Ras that have made it to the clinical despite massive efforts to target this pathway given its prevalence in human cancers, prompting the assertion that Ras proteins are “undruggable” (Baines et al., 2011; Cox et al., 2014). In addition to its ability to process all three major Ras isoforms, RRSP has also been shown to be effective toward the inhibition of various mutant forms of K-ras that are widely associated with human cancers (Antic et al., 2015). Our work provides additional evidence that RRSP is an effective inhibitor of Ras and establishes a potential use of this novel reagent for clinical purposes.

We also show that DP loss leads to activation of the ERK1/2–MAPK pathway in epidermal and cardiac models of DP deficiency. It is well established that elevated ERK1/2–MAPK signaling in the heart results in cardiac hypertrophy, an abnormal enlargement of the heart caused by increased cardiomyocyte size (Wang, 2007; Lorenz et al., 2009). Thus, it is plausible that abnormal ERK2 signaling could contribute to disease pathogenesis including cardiomyocyte hypertrophy in cardiac patients harboring mutations in DP (or factors that regulate its expression or localization). In epithelial cells, both activation of ERK2 signaling and loss or impairment of DP can lead to altered proliferation, migration, and differentiation (Matsubayashi et al., 2004; Setzer et al., 2004; Khavari and Rinn, 2007; Yang et al., 2012). That depletion of DP in the HaCaT keratinocyte cell line resulted in increased proliferation associated with elevated p-ERK1/2 levels is consistent with the concealed phase of ACM (Asimaki and Saffitz, 2012; Lyon et al., 2014). Our data provide a potential explanation for how DP loss could contribute to the concealed phase through regulation of Cx43 protein levels via modulation of Cx43 posttranslational modifications.

We identified Ras as a key link between DP and Cx43 regulation. Inhibition of Ras activity using a novel Ras inhibitor, RRSP, or by silencing with shRNA targeting K-Ras, demonstrated that ERK1/2 activation and associated loss of Cx43 expression was mediated by increased Ras expression and activity in DP-deficient cells. How DP regulates Ras mRNA levels is not yet understood. Although regulatory mechanisms controlling Ras transcription are not well characterized, one possibility is that loss of DP enhances the rate of Ras gene transcription via activation of transcription factors/cofactors. DP-dependent regulation of Ras transcript levels could also be through epigenetic mechanisms, for instance via the action of specific microRNAs that have been shown to be responsible for controlling Ras expression levels in various cell types (Shin et al., 2011; Wang et al., 2014; Zhang et al., 2014). To date, there have been no pharmacological inhibitors of Ras that have made it to the clinical despite massive efforts to target this pathway given its prevalence in human cancers, prompting the assertion that Ras proteins are “undruggable” (Baines et al., 2011; Cox et al., 2014). In addition to its ability to process all three major Ras isoforms, RRSP has also been shown to be effective toward the inhibition of various mutant forms of K-ras that are widely associated with human cancers (Antic et al., 2015). Our work provides additional evidence that RRSP is an effective inhibitor of Ras and establishes a potential use of this novel reagent for clinical purposes.

We also show that DP loss leads to activation of the ERK1/2–MAPK pathway in epidermal and cardiac models of DP deficiency. It is well established that elevated ERK1/2–MAPK signaling in the heart results in cardiac hypertrophy, an abnormal enlargement of the heart caused by increased cardiomyocyte size (Wang, 2007; Lorenz et al., 2009). Thus, it is plausible that abnormal ERK2 signaling could contribute to disease pathogenesis including cardiomyocyte hypertrophy in cardiac patients harboring mutations in DP (or factors that regulate its expression or localization). In epithelial cells, both activation of ERK2 signaling and loss or impairment of DP can lead to altered proliferation, migration, and differentiation (Matsubayashi et al., 2004; Setzer et al., 2004; Khavari and Rinn, 2007; Yang et al., 2012). That depletion of DP in the HaCaT keratinocyte cell line resulted in increased proliferation associated with elevated p-ERK1/2 levels is consistent with the concealed phase of ACM (Asimaki and Saffitz, 2012; Lyon et al., 2014). Our data provide a potential explanation for how DP loss could contribute to the concealed phase through regulation of Cx43 protein levels via modulation of Cx43 posttranslational modifications.
the possibility that DP-dependent regulation of cell behavior is mediated at least in part through its ability to attenuate ERK activity (Wan et al., 2007).

In this work, we use a previously published mouse model harboring cardiomyocyte specific conditional KO of DP using ventricular myosin light chain-2–Cre mice that recapitulates the pathological progression of ACM (Lyon et al., 2014). The authors observed wavefront propagation defects that were associated with loss of Cx43 expression. Our data suggest that DP loss triggers activation of the ERK1/2–MAPK pathway that then signals Cx43 for subsequent degradation by phosphorylation of the putative MAPK sites, S279/282. A conditional KO model whereby DP was deleted from the sinoatrial node (SAN) using the Hcn4-Cre-ERT2 mouse line has also been generated (Mezzano et al., 2016). Loss of DP from the SAN, which houses the pacemaker cells of the heart, resulted in beat-to-beat defects associated with loss of the pacemaker complex connexin, Cx45. Notably, no changes in Cx45 transcript level were detected, raising the possibility that Cx45 protein levels are regulated post-translationally. Along with the data reported in this study, these observations raise the possibility that DP controls Cx45 expression through modulation of specific Cx45 phosphosites that govern its dynamics.

The importance of Cx43 to the cardiac conduction system was highlighted in a recent study that implicated tissue resident macrophages present in mouse and human atrioventricular nodes in the regulation of cardiac electrical conduction (Hulsmans et al., 2017). The authors demonstrate that macrophages and cardiomyocytes are connected by Cx43-based gap junctions, whereby the resident macrophages function to modulate the electrical conduction of cardiomyocytes (Hulsmans et al., 2017). This finding could have important implications for both cardiac homeostasis and diseases such as ACM, in which increased cytokine expression and inflammation may contribute to disease progression (Corrado et al., 1997; Campian et al., 2010; Sen-Chowdhry et al., 2010; Asimaki et al., 2011).

The physiological relevance of our findings is supported by our analysis of cardiac tissue from a patient harboring a pathogenic PKP2 ACM mutation, which exhibited elevated levels of p-Cx43 S279/282 compared with control heart, reminiscent of that observed in murine DPcKO hearts. This was interesting in light of our previous observation that loss of PKP2 in cardiac cells promotes DP destabilization through proteasome-mediated degradation (Dubash et al., 2016). Although previous studies have shown that depletion of PKP2 resulted in defects in DP localization to cell junctions, effects on its protein expression levels appear to be exclusive to the cardiac system (Bass-Zubek et al., 2008; Godsel et al., 2010). This is likely because PKP2 is the lone isoform expressed in cardiac cells as opposed to epithelial cells that express PKP1 and PKP3 (Bass-Zubek et al., 2009).

In the same study, we demonstrated that a profibrotic signaling pathway triggered by the activation of TGF-β in response to PKP2 depletion was caused by the secondary loss of DP. This finding, coupled with the present observation that a PKP2 ACM mutation phenocopies the effects of DP loss, suggests the possibility that a portion of the pathogenic mutations in ACM associated with PKP2 may be corollary to its effects on DP expression and its loss.

Figure 8. Model of DP dependent regulation of Cx43 phosphorylation and degradation. (A) Loss of DP leads to elevated Ras gene expression that results in elevated Ras activation. Activation of the Ras signaling pathway leads to increased p-ERK1/2–MAPK levels that in turn phosphorylate Cx43 at S279/282. N-Cad, N-Cadherin; β-Cat, β-catenin; αT, αT-catenin; αE, αE-catenin; Dsg, Desmoglein; Dsc, Desmocollin. (B) Loss of DP also results in increased ubiquitination of Cx43. Cx43 is subsequently targeted for degradation via a lysosomal pathway. Ub, Ubiquitin.
Materials and methods
Isolation of NRVCs, cell culture, and mouse models
NRVCs were isolated as previously described (Dubash et al., 2016) from 1- to 3-d-old Sprague-Dawley rats (Charles River). Briefly, hearts were dissected from neonatal rats, enzymatically digested, and resuspended in M199 medium (Lonza) containing 10% FBS supplemented with 15 µM vitamin B12. Cells were then plated for 2 h on plastic cell culture dishes to separate the cardiac fibroblasts that adhere more rapidly than cardiomyocytes. The remaining cell suspension was then filtered through a 40-µM filter, spun down, and resuspended in M199 medium containing 10% horse serum, 15 µM vitamin B12, and BrdU. Plating of cells was then performed in six-well dishes or coverslips that had been coated with collagen type IV. Media was changed every 24–48 h, and adenoviral infection was performed 48 h after isolation. These protocols were conducted with the approval of the Northwestern University Institutional Animal Care and Use Committee, and all animal care protocols conform to National Institutes of Health (NIH) guidelines and the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. The HL-1 cell line was maintained with Claycomb medium (Sigma-Aldrich) supplemented with 10% FBS (Atlanta Biologicals), 0.1 mM norepinephrine, 2 mM l-glutamine, and penicillin/streptomycin solution (Sigma-Aldrich). Cells were grown on plastic dishes precoated with a solution of FN-0.02% gelatin.

To delete the DP gene in the mouse epidermis, conditional gene targeting was used whereby Exon 2 of the DP gene was flanked with LoxP sites and removed by breeding with mice transgenic for Cre recombinase under the control of the keratin 14 promoter (Vasioukhin et al., 2001). The K14-Cre transgenic and the DP-floxed (DSPflox/flox) mice were gifts from E. Fuchs. The K14-Cre transgenic mice targeting was used whereby Exon 2 of the DP gene was flanked with LoxP sites and removed by breeding with mice transgenic for Cre recombinase under the control of the keratin 14 promoter (Vasioukhin et al., 2001). The K14-Cre transgenic and the DP-floxed (DSPflox/flox) mice were gifts from E. Fuchs.

Transfections
Transient transfections were performed using DharmaFECT (GE Healthcare). Cells plated at 60–70% confluence were incubated with 0.2–5 µg DNA and DharmaFECT reagent premixed in serum-free media. Fresh medium was added 24 h after transfection, and samples were lysed or fixed 72 h after transfection.

Antibodies
The following primary antibodies were used in this study: NW6 rabbit anti-DP directed against the C-terminal domain of DP (Angst et al., 1990), 1407 chicken anti-Pg (Aves Laboratories), mouse anti-PK2 (65101; Progen), 115F mouse anti-DP (a gift from D. Garrod, University of Manchester, Manchester, UK), 12G10 mouse anti-α-tubulin (Developmental Studies Hybridoma Bank), rabbit anti-Cx43 (AB1728; EMD Millipore), mouse anti-Cx43 (MAB3068; EMD Millipore), IIF mouse anti-Cx43 (P. Lamp, Fred Hutchinson Research Center, Seattle, WA), mouse anti-N-cadherin (Invitrogen), mouse anti-β-catenin, rabbit anti-β-catenin (C2206; Sigma-Aldrich), mouse anti-Vinculin (V9131; Sigma-Aldrich), rabbit anti-phospho-Cx43 S279/282 (sc-129000-R; Santa Cruz Biotechnology), rabbit anti-phospho-Cx43 S279/282 (P. Lamp), rabbit anti-p-44/42 (9101; Cell Signaling Technologies), rabbit anti-total 44/22 (V1411; Promega), FK2 mouse anti-ubiquitylated proteins (04-263; EMD Millipore), 1296 anti-Myosin VI (S. Polo, FIRC Institute of Molecular Oncology, Milan, Italy), mouse anti-K-ras (WH0003845M1; Sigma-Aldrich), and mouse anti-Ras-GTP (26909; NewEast Biosciences). Peroxidase-conjugated anti-mouse, -rabbit, and -chicken secondary antibodies were used for Western blot analysis (Kiekegaard & Perry Laboratories). Alexa Fluor 488/568/647–conjugated goat anti–mouse, -rabbit, and -chicken secondary antibodies were used for immunofluorescence assays (Invitrogen).

Western blotting and coimmunoprecipitation assays
For analysis of protein expression levels, cells were washed once with PBS and lysed in urea sample buffer (8 M deionized urea, 1% sodium dodecyl sulfate, 10% glycerol, 60 mM Tris, pH 6.8, and 5% β-mercaptoethanol). Total protein concentrations were equalized, and samples were run on 7.5–12% SDS–PAGE gels. Gels were transferred to polyvinylidene fluoride membranes to be probed with primary and secondary antibodies against proteins of interest.

Cells used for coimmunoprecipitation assays were washed twice with PBS and lysed with modified RIPA buffer (500 mM NaCl, 50 mM Tris, pH 7.6, 10 mM MgCl2, 1% Triton X-100, 0.1% SDS, and 0.5% deoxycholate) supplemented with complete the lentiviral backbone pLKO (target sequence, 5′-CCCGCTATA CATTGGCGAGAACACTGATCTCAAGTGAGTTTTTGGT-3′; Sigma-Aldrich). Lentiviral particles were generated by the Northwestern University Skin Disease Research Center DNA/RNA Delivery Core. DP-specific murine siRNA oligonucleotides were obtained from GE Healthcare (sense sequences: 5′-GUG CAGAACUUGGUAACA-3′ and 5′-GCAUCCAGCUUCAGAA-3′). Cells were treated with the following reagents at the stated concentrations: 10 µg/ml cycloheximide, 100 µM chloroquine, 10 µM MG132, 5 µM U0126, and 2 nM RRSP.

DNA, siRNA, and shRNA constructs, adenovirus production, and chemical reagents
The DPII–GFP construct was generated with the QuikChange II XL site-directed mutagenesis kit (Agilent Technologies) whereby nucleotides 3,584–5,380 were spliced out of a GFP-tagged full-length DPI construct (Godsel et al., 2005). Adenoviral DPII was generated using Gateway recombination. Adenovirus was generated using the ViraPower Adenoviral Expression System (Invitrogen). K-Ras shRNA was generated from a rat K-Ras specific sequence within the

protease inhibitor cocktail (Roche). Samples were then incubated with 1 μg antibody against the protein of interest to be pulled down by rotating overnight at 4°C. Subsequently, samples were incubated with Protein A/G PLUS Agarose beads (Santa Cruz Biotechnology) for 30 min at 4°C. Samples were washed and eluted in Laemmli buffer with 5% β-mercaptoethanol, followed by SDS-PAGE and Western blot analysis.

**PLA**

Reagents required for PLA analysis were purchased from Sigma-Aldrich. Cells were rinsed and fixed as described for conventional immunofluorescence. Samples were then incubated with primary antibodies for the proteins of interest for 1 h at 37°C followed by incubation with secondary PLA probes for 1 h at 37°C. This was followed by a 30-min incubation with PLA ligase for ligation of nucleotides on corresponding probes. Subsequently, PLA polymerase was added for 100 min at 37°C to amplify the PLA signal, which results in red fluorescent dots if the antigens in question are in close proximity. Samples were mounted with PLA mounting medium containing DAPI, and ImageJ software (NIH) was used to quantify the number of PLA dots, which were then normalized to DAPI.

**qPCR**

Total RNA was isolated from cells using the RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions. Samples were then equalized for total RNA concentration, and cDNA was synthesized using the Superscript III First Strand kit (Invitrogen) according to the manufacturer’s instructions. qPCR was performed using SYBR Green PCR master mix (Applied Biosystems) along with the appropriate primers using a StepOne-Plus instrument (Applied Biosystems). Calculations for relative mRNA levels were performed using the ΔΔCt method using levels of GAPDH mRNA as a control. Relative levels were presented as fold-change values compared with control samples. Two-tailed Student’s t test was used to perform statistical analysis, with P < 0.05 considered statistically significant.

**Immunofluorescence and quantification of pixel intensity**

Cells grown on glass coverslips were washed once with PBS and fixed using 4% PFA or ice-cold methanol. Cells were then permeabilized with 0.2% Triton X-100 in PBS. Primary antibodies were added to coverslips and incubated at 37°C for 1 h followed by multiple washes in PBS. Alexa Fluor secondary antibodies (Thermo Fisher Scientific) were added and incubated for 30 min, followed by PBS washes and mounting of coverslips in polyvinyl alcohol (Sigma-Aldrich). Samples were visualized using a DMR microscope (Leica Microsystems) fitted with 40-Å (NA 1.0, Plan Fluotar) and 63-Å (NA 1.32, Plan Apochromat) objective lenses, and images were captured with an Orca 100 charge-coupled device camera (model C4742-95; Hamamatsu Photonics) and MetaMorph 7.7 imaging software (Molecular Devices). Mean fluorescence pixel intensity was quantified using raw, unsaturated 12-bit images with line or area tracing as stated using ImageJ. For quantification of junctional/ID fluorescence intensity, cell borders as marked by Pg signal using ImageJ line tracing and fluorescence intensity of Pg and the costained protein were assessed from the same line position. Subsequently, signal intensity values of the protein of interest were normalized to Pg intensity.

**Immunohistochemistry**

Tissue samples were fixed in 10% neutral-buffered formalin and embedded in paraffin. Paraffin-embedded sections were deparaffinized in sequential xylene and ethanol washes. Antibody retrieval for paraffin-embedded sections was performed by heating samples to 95°C in 0.01 M citrate buffer. Sections were blocked in 10% normal goat serum and incubated with primary and secondary antibodies for 1 h at 37°C. After mounting in polyvinyl alcohol, sections were visualized as described above.

**Surface biotinylation assay**

Cells were washed twice with ice-cold PBS and incubated with 2 mg/ml EZ-Link Sulfo-NHS-SS-biotin (Thermo Fisher Scientific) for 30 min at 4°C. Excess biotin was quenched with 100 mM glycine in PBS by washing three times for 10 min each. Cells were then washed with PBS and lysed in RIPA buffer (10 mM Tris, pH 7.5, 140 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 5 mM EDTA, 2 mM EGTA, and complete protease inhibitor). Lysates were centrifuged, and cell supernatants were normalized for total protein. 30 μl whole cell lysate was saved for input controls. Streptavidin beads (Thermo Fisher Scientific) were then used to pull down biotinylated proteins by rotating overnight at 4°C. After several washes in lysis buffer, samples were eluted using Laemmli sample buffer at 95°C and analyzed by Western blot as described above.

**Scrape loading dye transfer assay**

Cells were grown to confluence on glass coverslips and treated with appropriate KD conditions. A surgical blade was used to scrape lines in the confluent monolayer. Medium was aspirated and replaced with cell culture media premixed with 100 μl LY at 12 mg/ml stock (Thermo Fisher Scientific). Cells were incubated at 37°C for 15 min followed by PBS washes. Subsequently, samples were fixed in PFA and processed for immunofluorescence analysis as described above.

**Delivery of RRSP into cells**

NRVCMs seeded onto either six-well plates or glass coverslips were treated with the appropriate adenoviral constructs. Purification and cellular intoxication with LFNDUF5Vv and PA (referred to simply as RRSP) were conducted as previously described previously (Antic et al., 2015). Before treatment, cells in culture were provided with fresh medium. Next, 4.6 nM PA and 2 nM RRSP were added to the media for overnight incubation. Cells were either lysed in appropriate lysis buffer for Western blot analysis or fixed for image processing.

**Statistics**

All quantifications are presented as the mean ± SD. One-way ANOVA followed by Tukey’s post hoc analysis or Dunnett’s multiple comparison test was used for multiple comparisons. For data comparing two conditions, statistical differences were analyzed with a two-tailed Student’s t test. P < 0.05 was considered significant. For statistical analysis presented as fold change (bar
graphs), the mean of data from control samples was assigned a value of 1, and all other samples were calculated relative to the control. All densitometry quantification was normalized to respective loading controls.

Study approval
For the DPeKO mouse model, all mice were housed in accredited animal facilities, and the use and care of mice were in accordance with Northwestern University’s Institutional Care and Use Committee. For the DPeKO mouse model, all animal procedures were in full compliance with the guidelines approved by the University of California, San Diego, Animal Care and Use Committee. For human samples, informed consent was not required for the experiments performed in this study as all human samples were obtained as deidentified tissue and are covered by Beth Israel Deaconess Medical Center exemption protocols.

Online supplemental material
Fig. S1 shows that tissue sections from two independent DP ACM patients display a complete loss of DP and Cx43 localization at IDs. Fig. S2 demonstrates that depletion of DP in NRVCMs does not result in a significant change in Cx43 transcript levels. Fig. S3 shows that dose-dependent addition of RRSP to NRVCMs results in corresponding inhibition of p-ERK1/2 signal. Fig. S4 demonstrates that DPeKO epidermis does not display a significant change in KRAS, HRAS, or NRAS mRNA levels compared with WT tissue.

Acknowledgments
We thank Jeffrey Saffitz (Beth Israel Deaconess Medical Center) for providing ACM patient cardiac samples. We thank Gillian Fitz, Lisa Godels, and Jennifer Koetsier for their experimental/technical assistance. We also thank Jong Kook Park and Robert Lavker for their guidance in carrying out LY dye transfer assays. Sequencing services were performed at the Northwestern University Genomics Core Facility. Tissue sectioning and lentiviral particle production were performed in the Northwestern University Skin Disease Research Center (supported in part by P30AR057216).

This work was supported by NIH grant R37AR43380 and the J.L. Mayberry Endowment (to K.J. Green). P.D. Lampe is supported by NIH grant GM55632. F. Sheikh is supported by grants from NIH/National Heart, Lung, and Blood Institute (RO1 HL09780-06) and the Tobacco-Related Disease Research Program (24RT-022). K.J.F. Satchell is supported by a Translational Research Grant from Robert H. Lurie Comprehensive Cancer Center and the Northwestern Medicine Catalyst Fund. S. Polo is supported by the Associazione Italiana per la Ricerca sul Cancro (IG11627) and Worldwide Cancer Research (11-0051). C.Y. Kam was supported by a American Heart Association postdoctoral fellowship (15PRE25560138).

The authors declare no competing financial interests.

Author contributions: C.Y. Kam and K.J. Green designed the study, analyzed the data, and wrote the manuscript. C.Y. Kam performed most of the experiments. A.D. Dubash assisted with the generation of reagents and analysis of data. P. Lampe generated the phosphospecific Cx43 antibodies used for this study.

F. Sheikh generated the DPcKO mouse model. K.J.F. Satchell generated RRSP and provided technical assistance for its use. S. Polo and E. Magistrati provided reagents and participated in the preparation of the manuscript. All authors provided critical feed-back on the manuscript.

Submitted: 10 November 2017
Revised: 26 April 2018
Accepted: 11 June 2018

References
Alcalai, R., S. Metzger, S. Rosenheck, V. Meiner, and T. Chajek-Shaul. 2003. A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. J. Am. Coll. Cardiol. 42:319–327. https://doi.org/10.1016/S0735-1097(03)06284-8
Angst, B.D., L.A. Nilles, and K.J. Green. 1990. Desmoplakin II expression is not restricted to stratified epithelia. J. Cell Sci. 97:247–257.
Antic, I., M. Biancucci, Y. Zhu, D.R. Gius, and K.J. Satchell. 2015. Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain. Nat. Commun. 6:7396. https://doi.org/10.1038/ncomms8396
Asimaki, A., and J.E. Saffitz. 2012. Gap junctions and arrhythmogenic cardiomyopathy. Heart Rhythm. 9:992–999. https://doi.org/10.1016/j.hrthm.2011.11.024
Asimaki, A., and J.E. Saffitz. 2014. Remodeling of cell-cell junctions in arrhythmogenic cardiomyopathy. Cell Commun. Adhes. 21:13–23. https://doi.org/10.1016/j.cca.2013.876016
Asimaki, A., H. Tandri, H. Huang, M.K. Halushka, S. Gautam, C. Basso, G. Thiene, A. Tsatsopoulou, N. Protonotarios, W.J. McKenna, et al. 2009. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N. Engl. J. Med. 360:1075–1084. https://doi.org/10.1056/NEJMoa0808138
Asimaki, A., H. Tandri, E.R. Duffy, J.R. Winterfield, S. Mackey-Bojack, M.M. Picken, L.T. Cooper, D.J. Wilber, E.I. Marcus, C. Basso, et al. 2011. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 4:743–752. https://doi.org/10.1161/CIRCEP.111.964980
Axelsen, L.N., K. Calloe, N.H. Holstein-Rathlou, and M.S. Nielsen. 2013. Managing the complexity of communication: Regulation of gap junctions by post-translational modification. Front. Pharmacol. 4:130. https://doi.org/10.3389/fphar.2013.00130
Baines, A.T., D. Xu, and C.J. Der. 2001. Inhibition of Ras for cancer treatment: The search continues. Future Med. Chem. 3:1787–1808. https://doi.org/10.4155/fmc.11.121
Basso, C., G. Thiene, D. Corrado, A. Angelini, A. Nava, and M. Valente. 1996. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 94:983–991. https://doi.org/10.1161/01.CIR.94.5.983
Basso, C., D. Corrado, F.I. Marcus, A. Nava, and G. Thiene. 2009. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 373:1289–1300. https://doi.org/10.1016/S0140-6736(09)6256-7
Bass-Zubek, A.E., R.P. Hobbs, E.V. Amargo, N.J. Garcia, S.N. Hsieh, X. Chen, J.K. Wahl III, M.F. Deming, and K.J. Green. 2008. Plakophilin 2: A critical scaffold for PKCα that regulates intercellular junction assembly. J. Cell Biol. 181:605–613. https://doi.org/10.1083/jcb.200712133
Bass-Zubek, A.E., L.M. Godsel, M. Delmar, and K.J. Green. 2009. Plakophilins: Multifunctional scaffolds for adhesion and signaling. Curr. Opin. Cell Biol. 21:708–716. https://doi.org/10.1016/j.cceb.2009.07.002
Beardslee, M.A., J.G. Laing, E.C. Beyer, and J.E. Saffitz. 1998. Ras/Rap1-specific JNK ins: Multifunctional scaffolds for adhesion and signaling. J. Cell Biol. 143:605–673. https://doi.org/10.1083/jcb.143-605
Biancucci, M., A.E. Rabideau, Z. Lu, A.R. Loftis, B.L. Pentelute, and K.J.F. Satchell. 2017. Substrate recognition of MARCKS by PKA, RhoA, JNK, and IKKα. Proc. Natl. Acad. Sci. U.S.A. 114:13354–13359. https://doi.org/10.1073/pnas.1705704114
